Makar A.Ph., Kristensen G.B., Nesland J., Børmer O.P., Tropé C.G.
The Norwegian Radium Hospital, Departments of Gynecology and Pathology and The Central Laboratory, Oslo, Norway.
Int J Gynecol Cancer. 1993 Mar;3(2):116-121. doi: 10.1046/j.1525-1438.1993.03020116.x.
Serum CA 125 levels were evaluated in 26 patients with fallopian tube malignancies. CA 125 was elevated preoperatively in seven samples (median 178 U ml-1 range 41-19021 U ml-1), and postoperatively in eight of nine (89%) samples collected from patients with residual disease (median 109 U ml-1 range 10-1883 U ml-1) but only in one of seven (14%) samples from patients without residual disease (median 14, range 5-170 U ml-1) (P < 0.001). Changes in the serum CA 125 level during chemotherapy correlated with the clinical course of disease in 13 of 14 patients with a pre-chemotherapy serum CA 125 level> 35 U ml-1. Nine patients with clinical remissions showed decreasing serum CA 125 levels, one with clinically stable disease showed decreasing levels and four with disease progression showed increasing levels. Serum CA 125 levels were measured in four patients before second-look laparotomy. Two of three with positive findings at laparotomy had elevated serum CA 125 levels whilst the third had a normal level. One patient with negative findings at second-look surgery had a normal CA 125 level. Disease relapse was associated with elevated serum CA 125 levels in nine of 10 patients (median 108 U ml-1, range 27-38200 U ml-1). Using immunohistochemical staining, none of the tumors showed positive cytoplasmic staining for c-erbB-2 (NEU) oncogene. This report shows that CA 125 is a reliable tumor marker for monitoring patients with cancer of the fallopian tube during active treatment and follow-up.
对26例输卵管恶性肿瘤患者的血清CA 125水平进行了评估。7份样本术前CA 125升高（中位数178 U/ml，范围41 - 19021 U/ml），9份来自有残留病灶患者的样本中有8份（89%）术后CA 125升高（中位数109 U/ml，范围10 - 1883 U/ml），而7份来自无残留病灶患者的样本中只有1份（14%）术后升高（中位数14，范围5 - 170 U/ml）（P<0.001）。14例化疗前血清CA 125水平>35 U/ml的患者中，13例化疗期间血清CA 125水平的变化与疾病临床进程相关。9例临床缓解患者血清CA 125水平下降，1例病情稳定患者水平下降，4例疾病进展患者水平升高。4例患者在二次剖腹探查术前检测了血清CA 125水平。剖腹探查结果阳性的3例患者中有2例血清CA 125水平升高，第3例正常。二次手术结果阴性的1例患者CA 125水平正常。10例患者中有9例疾病复发与血清CA 125水平升高相关（中位数108 U/ml，范围27 - 38200 U/ml）。采用免疫组化染色，所有肿瘤均未显示c-erbB-2（NEU）癌基因的细胞质阳性染色。本报告表明，CA 125是监测输卵管癌患者积极治疗和随访期间的可靠肿瘤标志物。
